RxDoctor Payments Data

Sashalee Stewart, MD

Psychiatry · Charlotte, NCNPI 1093101222

Payments from drug & device makers

$5,541in general payments, 2019–2025

Across 205 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$681
  • Otsuka America Pharmaceutical, Inc.$604
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$379
  • Axsome Therapeutics, Inc.$354
  • Takeda Pharmaceuticals U.S.A., Inc.$304
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$1,05719%
  • Food & beverage$4,44780%
  • Education$361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,541 in reported general payments places this provider in the 85th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$47,088
Medicare patients
52
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LybalviOlanzapine/Samidorphan Malate21$31,888
RexultiBrexpiprazole18$24,992
Duloxetine Hcl53$1,606
Buspirone Hcl82$1,229
Olanzapine19$1,128
Venlafaxine Hcl ErVenlafaxine Hcl52$964
Trazodone Hcl63$945
Aripiprazole18$885
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine24$613
Hydroxyzine Hcl30$567
Bupropion XlBupropion Hcl29$495
Propranolol Hcl23$464
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine22$443
Lamotrigine41$413
Escitalopram Oxalate40$410

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi$79$31,88821 claims
Otsuka America Pharmaceutical, Inc.Rexulti$604$24,99218 claims
Almatica Pharma LLCSertraline Hcl$21$22132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →